Research programme: myostatin inhibitors - MYOS Corporation

Drug Profile

Research programme: myostatin inhibitors - MYOS Corporation

Latest Information Update: 31 Jul 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cloud Pharmaceuticals; MYOS Corporation
  • Class Small molecules
  • Mechanism of Action Furin modulators; Janus kinase 3 inhibitors; Myostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cachexia; Muscular atrophy

Most Recent Events

  • 17 Jul 2014 MYOS Corporation and Cloud Pharmaceuticals enter into a research and development agreement for myostatin inhibitors in USA for Muscular atrophy and Cachexia
  • 17 Jul 2014 Early research in Cachexia in USA (unspecified route)
  • 17 Jul 2014 Early research in Muscular atrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top